^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class      Levels    Values

      id             35    10631001 10631002 10631003    
                           11601006 11601007 13031001    
                           13031004 13581001 13581014    
                           13991002 13991004 13991007    
                           13991009 13991010 16591001    
                           16591003 16591006 17601002    
                           17601003 17601005 17601007    
                           17601012 17601014 17601025    
                           17661002 17661004 17661006    
                           19691001 19731001 19731002    
                           19731006 19831001 19831005    
                           19831008 19901003             
      AVISITN         2    4 12                          
      trtn            3    1 2 3                         
      SSNRISN         2    1 2                           
      SEXN            2    1 2                           
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class      Levels    Values

      wk12            2    0 1                           


                          Dimensions

              Covariance Parameters             3
              Columns in X                     39
              Columns in Z                      0
              Subjects                         35
              Max Obs per Subject               2


                    Number of Observations

          Number of Observations Read              60
          Number of Observations Used              60
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Number of Observations

          Number of Observations Not Used           0


                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       379.89707136                
          1              2       370.49401773      0.00594390
          2              1       369.46676069      0.00103400
          3              1       369.29920331      0.00005679
          4              1       369.29074284      0.00000022
          5              1       369.29071105      0.00000000


                   Convergence criteria met.                    
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           149.92
                UN(2,1)     id           101.87
                UN(2,2)     id           128.87


                        Fit Statistics

             -2 Res Log Likelihood           369.3
             AIC (Smaller is Better)         375.3
             AICC (Smaller is Better)        375.9
             BIC (Smaller is Better)         380.0


 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   2         10.61          0.0050


                 Type 3 Tests of Fixed Effects
 
                         Num     Den
      Effect              DF      DF    F Value    Pr > F

      BASE                 1    25.7      10.34    0.0035
      trtn                 2    22.5       0.38    0.6862
      wk12                 1    18.5       0.21    0.6525
      SSNRISN              1      24       0.01    0.9233
      BASE*wk12            1    18.8       0.55    0.4662
      trtn*SEXN            2    22.5       0.74    0.4890
      trtn*wk12            2    16.9       0.99    0.3934
      SEXN*wk12            1    16.8       2.43    0.1374
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                         Num     Den
      Effect              DF      DF    F Value    Pr > F

      trtn*SEXN*wk12       2      17       6.42    0.0084


                      Least Squares Means
 
                    Sex              Standard
 Effect      trtn   (N)   Estimate      Error     DF   t Value

 trtn*SEXN   1      1     -19.9132     9.0117   22.3     -2.21
 trtn*SEXN   1      2     -19.0439     4.4718   23.9     -4.26
 trtn*SEXN   2      1     -21.2393     5.3596   24.1     -3.96
 trtn*SEXN   2      2     -16.0375     4.3237   23.5     -3.71
 trtn*SEXN   3      1      -7.8962    11.3309   21.7     -0.70
 trtn*SEXN   3      2     -18.9409     3.9061     24     -4.85

 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                      Least Squares Means
 
                   Sex
Effect      trtn   (N)   Pr > |t|    Alpha      Lower      Upper

trtn*SEXN   1      1       0.0377     0.05   -38.5888    -1.2377
trtn*SEXN   1      2       0.0003     0.05   -28.2755    -9.8123
trtn*SEXN   2      1       0.0006     0.05   -32.2988   -10.1798
trtn*SEXN   2      2       0.0011     0.05   -24.9713    -7.1037
trtn*SEXN   3      1       0.4933     0.05   -31.4135    15.6211
trtn*SEXN   3      2       <.0001     0.05   -27.0024   -10.8795
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class       Levels    Values

      id              21    10631001 10631002 10631003    
                            11601006 11601007 13031001    
                            13581001 13581014 13991002    
                            13991004 13991007 13991009    
                            16591001 17601005 17601007    
                            17601014 17661004 19731002    
                            19731006 19831001 19901003    
      AVISITN          2    4 12                          
      SSNRISN1         2    0 1                           


                          Dimensions

              Covariance Parameters             3
              Columns in X                     12
              Columns in Z                      0
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Subjects                         21
              Max Obs per Subject               2


                    Number of Observations

          Number of Observations Read              37
          Number of Observations Used              37
          Number of Observations Not Used           0


                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       225.21097308                
          1              2       206.63206161      0.00799548
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          2              1       206.15061126      0.00195589
          3              1       205.97703959      0.00009406
          4              1       205.96930967      0.00000038
          5              1       205.96927947      0.00000000


                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           143.04
                UN(2,1)     id           135.61
                UN(2,2)     id           149.49
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                        Fit Statistics

             -2 Res Log Likelihood           206.0
             AIC (Smaller is Better)         212.0
             AICC (Smaller is Better)        213.1
             BIC (Smaller is Better)         215.1


                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   2         19.24          <.0001


 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                          Num     Den
     Effect                DF      DF    F Value    Pr > F

     BASE                   1      15       1.17    0.2966
     trtn1                  1      15       0.08    0.7764
     wk12                   1    11.1       8.04    0.0161
     SSNRISN1               1      15       0.02    0.8791
     SEXN1                  1      15       1.31    0.2701
     BASE*wk12              1    11.1      12.69    0.0044
     trtn1*SEXN1            1      15       0.06    0.8161
     trtn1*wk12             1      11       0.29    0.5986
     wk12*SEXN1             1    10.9       1.39    0.2633
     trtn1*wk12*SEXN1       1    10.9      18.06    0.0014


 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Estimates
 
                              Standard
Label               Estimate     Error    DF  t Value  Pr > |t|

1 ACT-PBO  Week 4     2.1616   15.3161    15     0.14    0.8896
2 ACT-PBO  Week 4    -1.6908    5.8460    15    -0.29    0.7764
1 ACT-PBO  Week 12  -24.5303   15.7528  12.7    -1.56    0.1440
2 ACT-PBO  Week 12   -0.2143    6.1722  13.7    -0.03    0.9728

                           Estimates
 
       Label                Alpha       Lower       Upper

       1 ACT-PBO  Week 4     0.05    -30.4815     34.8046
       2 ACT-PBO  Week 4     0.05    -14.1499     10.7684
       1 ACT-PBO  Week 12    0.05    -58.6409      9.5803
       2 ACT-PBO  Week 12    0.05    -13.4813     13.0527
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Contrasts
 
                                           Num    Den
 Label                                      DF     DF   F Value

 Treatment*Week 4*Subgroup Interaction       1     15      0.06
 Treatment*Week 12*Subgroup Interaction      1   12.8      2.10

                           Contrasts
 
        Label                                    Pr > F

        Treatment*Week 4*Subgroup Interaction    0.8161
        Treatment*Week 12*Subgroup Interaction   0.1713
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Model Information

     Data Set                     WORK.DBRW_DATA           
     Dependent Variable           CHG                      
     Covariance Structure         Unstructured             
     Subject Effect               id                       
     Estimation Method            REML                     
     Residual Variance Method     None                     
     Fixed Effects SE Method      Kenward-Roger            
     Degrees of Freedom Method    Kenward-Roger            


 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                    Class Level Information
 
      Class       Levels    Values

      id              26    10631001 10631003 11601006    
                            13031001 13031004 13581001    
                            13581014 13991010 16591003    
                            16591006 17601002 17601003    
                            17601007 17601012 17601025    
                            17661002 17661004 17661006    
                            19691001 19731001 19731002    
                            19731006 19831001 19831005    
                            19831008 19901003             
      AVISITN          2    4 12                          
      SSNRISN1         2    0 1                           


 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                          Dimensions

              Covariance Parameters             3
              Columns in X                     12
              Columns in Z                      0
              Subjects                         26
              Max Obs per Subject               2


                    Number of Observations

          Number of Observations Read              44
          Number of Observations Used              44
          Number of Observations Not Used           0


 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                       Iteration History
 
  Iteration    Evaluations    -2 Res Log Like       Criterion

          0              1       284.50194142                
          1              2       277.10607085      0.00155887
          2              1       276.91208075      0.00011980
          3              1       276.89841542      0.00000094
          4              1       276.89831376      0.00000000


                   Convergence criteria met.                    


                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(1,1)     id           157.60
                UN(2,1)     id           105.27
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Covariance Parameter Estimates
 
                Cov Parm    Subject    Estimate

                UN(2,2)     id           141.32


                        Fit Statistics

             -2 Res Log Likelihood           276.9
             AIC (Smaller is Better)         282.9
             AICC (Smaller is Better)        283.7
             BIC (Smaller is Better)         286.7


 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                Null Model Likelihood Ratio Test
 
                  DF    Chi-Square      Pr > ChiSq

                   2          7.60          0.0223


                 Type 3 Tests of Fixed Effects
 
                          Num     Den
     Effect                DF      DF    F Value    Pr > F

     BASE                   1    18.5       5.75    0.0272
     trtn2                  1    18.9       1.43    0.2458
     wk12                   1      14       0.29    0.6002
     SSNRISN1               1    18.2       0.06    0.8047
     SEXN1                  1    18.2       0.82    0.3759
     BASE*wk12              1    14.1       0.02    0.8820
     trtn2*SEXN1            1    18.3       1.96    0.1781
     trtn2*wk12             1      14       2.53    0.1342
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                 Type 3 Tests of Fixed Effects
 
                          Num     Den
     Effect                DF      DF    F Value    Pr > F

     wk12*SEXN1             1    12.3       0.06    0.8079
     trtn2*wk12*SEXN1       1    12.8       0.89    0.3635


                           Estimates
 
                               Standard
Label                Estimate     Error    DF  t Value  Pr > |t|

1 ACT-PBO    Week 4  -14.2326   13.8819  18.2    -1.03    0.3187
2 ACT-PBO  Week 4      7.2264    6.0328  18.9     1.20    0.2458
1 ACT-PBO  Week 12   -11.3279   13.6012  13.9    -0.83    0.4190
2 ACT-PBO  Week 12    -1.3217    6.1512  14.7    -0.21    0.8328

 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Estimates
 
      Label                 Alpha       Lower       Upper

      1 ACT-PBO    Week 4    0.05    -43.3799     14.9146
      2 ACT-PBO  Week 4      0.05     -5.4046     19.8575
      1 ACT-PBO  Week 12     0.05    -40.5207     17.8649
      2 ACT-PBO  Week 12     0.05    -14.4525     11.8091


                           Contrasts
 
                                           Num    Den
 Label                                      DF     DF   F Value

 Treatment*Week 4*Subgroup Interaction       1   18.3      1.96
 Treatment*Week 12*Subgroup Interaction      1   14.1      0.44

 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz Pharmace
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.3
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Effic
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Ful

                      The Mixed Procedure

                           Contrasts
 
        Label                                    Pr > F

        Treatment*Week 4*Subgroup Interaction    0.1781
        Treatment*Week 12*Subgroup Interaction   0.5178
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 total sco
^S={}Note:The Modified Full Analysis Set includes all participan
^S={}Note: The baseline (Day -1) value is generally defined as t
^S={}Note:The CAPS-5 total score is the sum of the 20 item-score
^S={}Note: All ICEs are addressed using the treatment policy str
^S={}Note: The LS means, SEs,LS Mean Diff, 95% (CI) and p-value 
^S={}Note: The randomization stratification factor will be remov
^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\p
